GLP3-RT

Original price was: $59.99.Current price is: $54.99.

High-Purity GLP3-RT | Triple Receptor Agonist for Metabolic Research

GLP3-RT (also known as retatrutide) is a next-generation research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. Designed for laboratory investigation of advanced metabolic pathways.

GLP3-RT is the research community’s designation for retatrutide (LY3437943), a synthetic triple hormone receptor agonist. Unlike mono-agonists (semaglutide) or dual agonists (tirzepatide), GLP3-RT engages three distinct metabolic receptors in a single molecule, making it a compound of high scientific interest for studies on weight regulation, energy expenditure, and hepatic fat metabolism.

What is GLP3-RT? 
GLP3-RT refers to retatrutide, an investigational peptide developed by Eli Lilly. There is no official “GLP-3 receptor.” The “GLP-3” or “GLP3-RT” label is informal shorthand used in research and peptide communities because the molecule activates three receptors:

  • GLP-1 receptor (appetite and insulin regulation)
  • GIP receptor (incretin amplification)
  • Glucagon receptor (energy expenditure and fat oxidation)

This triple-agonist profile distinguishes it from earlier generations of incretin-based peptides and has driven significant research attention.

How GLP3-RT Works – Mechanism of Action 
GLP3-RT is a 39-amino-acid peptide with a fatty-acid side chain that extends its duration of action. By activating GLP-1 and GIP receptors, it supports appetite control and glucose-dependent insulin secretion. Concurrent glucagon receptor activation promotes increased energy expenditure and hepatic fat metabolism — a combination not present in dual agonists. This multi-pathway approach is why retatrutide has shown robust results in clinical-stage trials.

Key Research Findings 
Published Phase 2 data (NEJM) demonstrated mean body-weight reductions of up to 24.2% at the highest dose over 48 weeks, along with reductions in liver fat. Subsequent Phase 3 TRIUMPH program results have confirmed substantial weight loss (often exceeding 20% at higher doses), improved glycemic control in participants with type 2 diabetes, and benefits in related conditions such as knee osteoarthritis and obstructive sleep apnea in specific subgroups.

These findings position GLP3-RT as a valuable research tool for laboratories studying next-generation metabolic interventions. Note: Retatrutide remains investigational and is not approved by the FDA or any regulatory body for human use.

Comparison Table

Nickname Receptors Targeted Example Compound Status
GLP-1 GLP-1 only Semaglutide FDA approved
Dual (GLP-2) GLP-1 + GIP Tirzepatide FDA approved
GLP3-RT GLP-1 + GIP + Glucagon Retatrutide Investigational

Product Features & Quality Assurance 
Our GLP3-RT is supplied as high-purity lyophilized powder (≥99% by HPLC), third-party tested, and accompanied by a Certificate of Analysis (COA). Available in multiple vial sizes to suit different research protocols. Strictly intended for laboratory and in-vitro research use only. Not for human or veterinary consumption.

Why Researchers Choose Our GLP3-RT

  • Independently verified purity and identity
  • Transparent batch testing and COA
  • Consistent quality for reproducible experiments
  • Proper storage and handling guidance
  • Focus on research integrity and compliance

Reviews

There are no reviews yet.

Be the first to review “GLP3-RT”

Your email address will not be published. Required fields are marked *